3:42 PM
 | 
May 15, 2019
 |  BC Extra  |  Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start
Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30 million milestone payment to Principia. Sanofi has exclusive, worldwide rights to the covalent Btk inhibitor from Principia under a 2017 deal.

Agios planning sNDA for Tibsovo in cholangiocarcinoma
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >